Navigation Links
Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
Date:9/9/2009

on 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements reflect Cumberland's current views with respect to future events, based on what it believes are reasonable assumptions. No assurance can be given, however, that these events will occur. As with any business, all phases of Cumberland's operations are subject to influences outside its control. Any one, or a combination, of these risk factors could materially affect the results of the Cumberland's operations. These factors include among other things, market conditions, the commercialization of Caldolor, Cumberland's dependence on Acetadote and Kristalose to generate almost all of its revenues, intense competition from existing and new products, which could diminish the commercial potential of Cumberland's products, an inability of manufacturers to produce Cumberland's products on a timely basis or a failure of manufacturers to comply with stringent regulations applicable to pharmaceutical drug manufacturers, maintaining and building an effective sales and marketing infrastructure, Cumberland's ability to identify and acquire rights to products, government regulation, the possibility that Cumberland's marketing exclusivity and patent rights may provide only limited protection from competition, and other factors discussed in our Registration Statement declared effective by the SEC on August 10, 2009. There can be no assurance that the results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequences to or effects on the Company or its business and operations. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to ref
'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Orion ICG, LLC Announces Acquisition of Cumberland Therapy Services, Inc.
2. Cumberland Pharmaceuticals Announces Appointments
3. Cumberland Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 27, 2009
4. Cumberland Pharmaceuticals Reports Second Quarter 2009 Financial Results
5. Cumberland Pharmaceuticals to Present at UBS Global Life Sciences Conference in New York on September 21, 2009
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 2015 Colleen’s Dream Foundation , with ... to the UNMC to support ovarian cancer research conducted by ... member of the Colleen’s Dream Foundation Board of Directors. , ... to date for Colleen’s Dream Foundation and they couldn’t have ... “Dr. Wang is a rising star in the ovarian cancer ...
(Date:6/2/2015)... 02, 2015 While the movie box ... comic books, comic books themselves are stepping into a ... Nations plans to produce educational comics in multiple languages ... for Sustainable Development - an international effort to address ... health, education, sustainable energy, inequality, climate change and more. ...
(Date:6/2/2015)... CA (PRWEB) June 02, 2015 ... scholarship fund set up by current and former students ... a beloved faculty member from 2002 until his death ... keen intelligence, and depth of feeling, as well as ... fairytales. His capacities as an analyst, teacher, and writer ...
(Date:6/1/2015)... The National Association of Professional ... a 2015-2016 inductee into its VIP Woman of the ... for leadership in business. NAPW is the nation’s leading ... 700,000 members and over 200 operating Local Chapters. , ... award,” said NAPW President Star Jones. “Her knowledge and ...
(Date:6/1/2015)... June 02, 2015 The National ... Cade as a 2015-2016 inductee into its VIP ... this prestigious distinction for leadership in business. NAPW is ... boasting more than 700,000 members and over 200 operating ... this important honor,” said NAPW President Star Jones. “Her ...
Breaking Medicine News(10 mins):Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 2Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 3Health News:Can Comics Help the United Nations Save the World? 2Health News:Can Comics Help the United Nations Save the World? 3Health News:Pacifica Graduate Institute - Mythological Studies Students Establish Memorial Scholarship to Honor Dr. V. Walter Odajnyk 2Health News:Pacifica Graduate Institute - Mythological Studies Students Establish Memorial Scholarship to Honor Dr. V. Walter Odajnyk 3Health News:National Association of Professional Women Inducts Lynn Lester, Director of Clinical Operations/CEO, Recovery Treatment Center, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Linda Cade, Senior Product Manager at Sage, Into its VIP Professional Woman of the Year Circle 2
... drug named bivalirudin is turning out to be a better ... conditions, for instance heart attacks. ,Lead researcher ... of cardiovascular research and education at Columbia University said, "We ... We find that compared to heparin, it is just as ...
... infinite variety', wrote the famous Dramatist and Poet, William Shakespeare ... woman is quite an enigma and undoubtedly, there is more ... 'weaker sex' or the 'fair sex', they often find themselves ... nature has endowed unique qualities in a man and woman, ...
... of 4 cases of botulism following cosmetic injections to ... concentrated, //unlicensed preparation that resulted in toxin levels up ... to a report. ,Botulism is a rare paralytic ... Clostridium botulinum and toxin-producing strains of Clostridium baratii and ...
... to deformities, says a new study. // ,Each ... a large number of ligaments, tendons, blood vessels and nerves ... running. ,Excess weight and obesity can damage ... particular risk of deformities and abnormalities, said Stewart Morrison, a ...
... order to implement better cancer care to patients certain ... published in the British Medical journal. The team of ... Clinical Excellence (NICE) should amend some of their modes ... needs of cancer patients. More planning is essential to ...
... by researchers at Yale School of Medicine has reported about ... aggressive 'wet' form of age-related macular degeneration (AMD), the most ... ,AMD causes light-sensitive cells in the retina to break ... two forms of AMD, the 'dry' is more common than ...
Cached Medicine News:Health News:Men are from Mars and Women from Venus, but why on Earth are Women so Woefully Wronged? 2Health News:Men are from Mars and Women from Venus, but why on Earth are Women so Woefully Wronged? 3Health News:Highly-Concentrated Botulinum Preparation Can Result in Severe Illness 2Health News:Highly-Concentrated Botulinum Preparation Can Result in Severe Illness 3Health News:Cancer Care Compromised by Cost 2Health News:Gene Linked With Aggressive 'Wet' Form Of AMD 2
(Date:6/2/2015)... A new report by the Global Sanitation ... across 13 countries bring an end to open defecation. ... Progress Report details how its financial support for nationally-led ... communities become open-defecation free, improved toilets for 4.2 million ... hand-washing facilities. The Progress Report highlights cumulative ...
(Date:6/2/2015)... June 2, 2015 ... mejora  de 7,9 meses en la supervivencia libre ... con cáncer colorrectal metastático inoperable (mCRC) tratados  en ... Y-90 más quimioterapia    Los beneficios ... directamente al hígado con la quimioterapia sistémica actual ...
(Date:6/2/2015)... CHICAGO e MADRID , ... orale (abstract 10503) al meeting annuale della American Society ... i dati dello studio multicentrico di fase 3 SAR3007, ... Janssen , LLC (Janssen), hanno evidenziato un significativo miglioramento ... con trabectedina (YONDELIS ® ) rispetto al trattamento con ...
Breaking Medicine Technology:Global Sanitation Fund Reports Major Sanitation & Hygiene Advances for Seven Million People in 13 Countries 2Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 2Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 3Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 4Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 5Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 6Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 7Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 8PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 2PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 3PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 4PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 5PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 6
... Loss, Lower Blood Sugar and Improved A1CHORSHAM, Pa., April 21 ... loss program that delivers to your door, today announced the ... specifically for the approximately 24 million Americans with diabetes, as ... for diabetes. In a clinical study at Temple ...
... clinical trial strategies for personalized approach to cancer ... a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) ... preclinical study, which utilized RNA interference (RNAi) and ... vulnerability" - that enhance the anti-tumor response to ...
Cached Medicine Technology:New Weight Loss Hope for People with Diabetes 2New Weight Loss Hope for People with Diabetes 3New Weight Loss Hope for People with Diabetes 4New Weight Loss Hope for People with Diabetes 5New Weight Loss Hope for People with Diabetes 6Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 2Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 3Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 4
... developed in surgeon's desire to have the ... instrument with the strength to maneuver into ... bending or breaking. Arthrotek Hand Instruments are ... the surgeon's hand. This new generation of ...
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
Medicine Products: